Shinhan Venture Investment
VC Fund
Seoul, South Korea
Shinhan Venture Investment is a VC fund in Seoul focused on Biotechnology and Health Care. Shinhan Venture Investment operates as an investment company. Shinhan Venture Investment focuses on earlier-stage venture capital investments and later-stage control investments opportunities derived from the latest megatrends such as the aging population, disruptive technologies, IT convergence, alternative energy and etc.
- Total investments:
- 210
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Shinhan Venture Investment invests in
Stages Shinhan Venture Investment invests in
Countries Shinhan Venture Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $2.2M–$26M
- Series B
- $4.8M–$45M
- Series C
- $7.6M–$71M
Investment Focus
Industry
- Biotechnology 27 (13%)
- Health Care 26 (12%)
- Software 24 (11%)
- Manufacturing 23 (11%)
- Information Technology 23 (11%)
Stage
- Series B 42 (20%)
- Series A 40 (19%)
- Series C 31 (15%)
- Seed 30 (14%)
- Funding Round 28 (13%)
Country
- South Korea 158 (75%)
- United States 14 (7%)
- Japan 3 (1%)
- India 2 (1%)
- Indonesia 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ho Jun Lee
Managing Director & GM
|
Managing Director & GM | Total investments: 0 | Find email | |
|
Kim Ji-won
Deputy General Manager
|
Deputy General Manager | Total investments: 1 | Find email | |
|
Lee Beom su
Head
|
Head | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Linq
|
We are creating ‘hyper-automated insurance platforms’ to comprehensively support underwriters and claim adjusters and to facilitate communication between insurers and reinsurers using AI and deep learning. | $22M / Series A / Jul 02, 2026 | |
Nventric
|
Nventric is a medical device company that develops core products for neurovascular, coronary heart, and peripheral vascular applications. | $22.6M / Venture - Series Unknown / Jun 10, 2026 | |
Subtle Medical
|
Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow.The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant tofacilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers.Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. | $33M / Series C / Jun 02, 2026 | |
XCENA
|
XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $135M / Series B / May 29, 2026 | |
Dnotitia
|
Dnotitia is a pioneering AI (Artificial Intelligence) company driving innovative value by integrating AI and data. Founded in October 2023, Dnotitia specializes in developing; Seahorse, a high-performance vector database powered by its proprietary Vector Data Processing Units (VDPU), and Mnemos, a cutting-edge service solution for Large LanguageModels (LLMs). The company also leads the development of sLMs (Small Language Models) and Retrieval-Augmented Generation (RAG) systems, crucial for advancing generative AI technologies and positioning itself at the forefront of AI technology. | $63.4M / Series A / Apr 21, 2026 | |
Upstage
|
Upstage AI develops artificial intelligence technologies focused on large language models and document processing systems designed to support enterprise workflows. Its platform includes tools that convert unstructured data such as PDFs, scans, and emails into structured, machine-readable formats, enabling downstream analysis and automation. Thecompany also provides models like its Solar LLM, which are optimized for tasks such as text generation, information extraction, and question answering within business environments. Its solutions are applied across industries including finance, healthcare, insurance, and manufacturing to handle tasks like document parsing, data extraction, and workflow automation. Additionally, its services can be deployed through APIs, cloud environments, or on-premise systems to integrate with existing enterprise infrastructure. | $121.7M / Series C / Apr 15, 2026 | |
Labrador Labs
|
LABRADOR LABS began as an academic research collaboration initiative to develop an automated analytic method for detecting both known and new vulnerabilities. | $9.7M / Series B / Mar 25, 2026 | |
12 Pharmacy
|
12 Pharmacy is a pharmaceutical company that specializes in manufacturing and providing medicines and services for veterinary hospitals. | Series A / Jan 14, 2026 | |
Biocom
|
Biocom is a green bio management company. | $2.6M / Series A / Dec 29, 2025 | |
WorkerInSpace
|
WorkerInSpace is an aerospace startup focused on On-Orbit Servicing (OOS) and In-space Servicing, Assembly, and Manufacturing (ISAM) technologies for satellites and space infrastructure. The company develops versatile robotic spacecraft capable of satellite refueling, repair, towing, inspection, debris removal, and in-space manufacturing to extendsatellite lifespan and support sustainable space operations. | $6.1M / Seed / Dec 03, 2025 | |
| See all 210 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Shinhan Venture Investment invest in?
Shinhan Venture Investment invests primarily in Biotechnology, Health Care and Software startups, most often at Series B and Series A stage. Most of the 210 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shinhan Venture Investment's check size?
Shinhan Venture Investment typically joins rounds of $2.2M–$26M at Series A, $4.8M–$45M at Series B and $7.6M–$71M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shinhan Venture Investment participates in.
How do I contact Shinhan Venture Investment?
Public channels for Shinhan Venture Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shinhan Venture Investment?
The team at Shinhan Venture Investment includes Ho Jun Lee (Managing Director & GM), Kim Ji-won (Deputy General Manager) and Lee Beom su (Head). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
